Sign in

NCT07348237CompletedPhase 1

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-2828 in Participants With Renal Impairment

Source: ClinicalTrials.gov · Last updated 15 Sept 2026

Brief summary (registry, in English)

The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
18 (actual)
First submitted
9 Jan 2026
Start date
2 Mar 2026
Primary completion date
1 Sept 2026
Lead sponsor
Merck Sharp & Dohme LLC
NCT number
NCT07348237

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 18
  • From 2 Mar 2026 to the primary completion date, 1 Sept 2026
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • The main inclusion criteria include but are not limited to the following:
  • Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor.
    • Severe Renal Impairment Participants:
  • Has an estimated glomerular filtration rate (eGFR) \< 30 mL/min), but is not on hemodialysis (HD)
    • ESRD on HD Participants:
  • Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for \> 3 months prior to study entry
    • The main exclusion criteria include but are not limited to the following:
    • Renal Impairment Participants:
  • History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
    • Healthy Matched Control Participants:
  • History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.

Age in the registry: 24 years to 85 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Floridian Clinical Research ( Site 0001)
Coordinator of this site? Confirm its status
Miami LakesUnited StatesUnknown status
Panax Clinical Research ( Site 0003)
Coordinator of this site? Confirm its status
Miami LakesUnited StatesUnknown status
Orlando Clinical Research Center ( Site 0002)
Coordinator of this site? Confirm its status
OrlandoUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.